US FDA Nod for Glenmark's Manufacturing Facility in North Carolina
Glenmark Pharmaceuticals has announced that the US FDA has provided its first supplemental Abbreviated New Drug Application (sANDA) approval for the company’s manufacturing facility in Monroe, North Carolina. The approval covers Atovaquone and Proguanil Hydrochloride Tablets, 250 mg/100 mg and 62.5 mg/25 mg, a generic version of GlaxoSmithKline’s Malarone (atovaquone and proguanil hydrochloride) Tablets.
“This approval is an important milestone for our US business, as the Monroe, N.C. site will expand our portfolio by providing the manufacturing foundation for future product approvals,” said Mr. Robert Matsuk, President, North America & Global API at Glenmark Pharmaceuticals. “Additionally, we are pleased that the investment we’ve made in our site will continue to create new, high-quality jobs in the Monroe community, where we have a commitment to long-term growth and expansion.”
The Monroe, North Carolina facility is Glenmark’s first manufacturing site in the US, designed to manufacture a variety of fixed dose pharmaceutical formulations. Glenmark has invested more than $100-mn in the facility with plans for further expansion in coming years. At peak capacity, the site is anticipated to produce 300-400 mn tablets and capsules, 20-25 mn vials and pre- filled syringes and 25-30 mn ampoules for inhaled formulations.
2026-10-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Nirma acquires majority stake in Glenmark Life Sciences
-
U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List
-
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
“No Artificial Colors” Gets Redefined—Why FDA’s Labeling Shift Is Roiling the Food Additive World
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
FDA Reopens BHA Review—Why One Preservative Is Becoming a Global Wake-Up Call for Food Additives
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment
-
U.S. Congress Passes Bill Authorizing Tariffs of Up to 100% on Major Buyers of Russian Energy
Recommend Reading
-
UK Opens Formal Review of AkzoNobel–Axalta $25 Billion Merger
-
U.S. Formally Imposes Antidumping and Countervailing Duty Orders on Chinese L-Lysine
-
3M, DuPont and Honeywell Must Face Firefighters’ PFAS Turnout-Gear Lawsuit
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs
-
Premium Global Chemical Sourcing Requests (15-19 Nov 2025)
-
Supply-side disruptions persist, lithium carbonate prices continue to rise
-
Business Society’s Trend Analysis for Lithium Carbonate on September 14, 2026: Volatile Fluctuations
-
Premium Global Chemical Sourcing Requests (27-29July, 2026)
-
This week, the Chinese propylene oxide market shows a significant downward trend